Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
Create a narrative
Hikma Pharmaceuticals Community
LSE:HIK Community
1
Narratives
written by author
0
Comments
on narratives written by author
30
Fair Values set
on narratives written by author
Community Investing Ideas
Hikma Pharmaceuticals
Popular
Undervalued
Overvalued
Hikma Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
US, Europe, And MENA Expansion Will Boost Global Pharmaceutical Demand
Key Takeaways Expanding global manufacturing and focus on complex generics position Hikma to benefit from rising pharmaceutical demand and the shift toward more cost-effective health solutions. Robust R&D, resilient MENA operations, and strong supply chain compliance provide higher-margin growth, stable performance amid regional volatility, and greater reliability than import-dependent peers.
View narrative
UK£25.09
FV
26.8% undervalued
intrinsic discount
5.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
21
users have followed this narrative
9 days ago
author updated this narrative
Your Valuation for
HIK
HIK
Hikma Pharmaceuticals
Your Fair Value
UK£
Current Price
UK£18.36
7.1% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-806m
4b
2015
2018
2021
2024
2025
2027
2030
Revenue US$4.3b
Earnings US$493.1m
Advanced
Set Fair Value